CORRESPONDENCE
We read with great interest the Review by Harrys Torres and Marta Davila (Reacti vation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat. Rev. Clin. Oncol. 9, 156-166; 2012) on the reactivation of the hepatitis B virus (HBV) that occurs in patients with cancer after they undergo chemotherapy. 1 Although the Review pro vided a broad overview of the reactivation of HBV, the authors did not touch on the rescue treatments for acute exacerbations of hepati tis B. According to previous studies on this specific issue, 2 and our case series report, 3 the mortality of patients with HBV reactivation can be as high as 20-50%. 2, 3 However, there has been no adequate research on rescue treatments for the acute exacerbations of hepatitis B, which can seriously affect the survival of patients with this condition.
Antiviral prophylaxis with nucleotide ana logues, such as lamivudine, has been shown to be effective in preventing HBV reactiva tion in patients receiving chemotherapy. 1 However, HBV reactivation cannot be completely eliminated. 3 According to some reports, HBV reactivation can be induced by discontinuing antiviral agents or viral breakthrough. 2, 4 Viral breakthrough that occurs during nucleotide analogue treat ment is generally caused by poor adherence to therapy or selection of drugresistant HBV variants. The possibility of drug resistance differs for each nucleotide analogue; lami vudine, telbivudine and adefovir present the highest rates of resistance whereas entecavir and tenofovir each have a high barrier to resistance. Moreover, reactivation of HBV can range from asympto matic, selflimiting, anicteric hepatitis to severe, potentially fatal, progressive decompensated hepatitis. 1, 5 Indeed, for patients with confirmed HBV reactivation that was triggered by discon tinuation of prophylaxis, nucleotide ana logues with potent HBV inhibition (such as entecavir and tenofovir) should be given as rescue antiviral therapy before alanine ami notransferase elevation occurs to decrease the risk of developing liver failure. Given that the 1year cumulative rate of resistance to lamivudine can be as high as 24%, both 6 Above all, rescue antiviral therapy should be commenced upon diagnosis of HBV reactivation and before alanine aminotransferase elevation to reduce the risk of developing acute liver failure.
Meanwhile, appropriate intensive care is critical in the management of patients with severe HBV reactivation after chemotherapy, especially for those who have developed acute liver failure. 7 However, nonspecific therapies such as rescue antiviral therapy commenced after a diagnosis of acute liver failure are of unproven benefit for patients who did not receive rescue nucleotide analogues before alanine aminotransferase elevation. Indeed, to the best of our knowledge, our article is the only primary research report focused on the prognosis and treatment of severe HBV reactivation after immuno chemotherapy. 3 According to our results, rescue anti viral therapy that provides rapid reduction of viraemia might improve survival. This finding was partially supported by research on the severe acute exacerbation of chronic HBV infection, which also demonstrated that antiviral therapy might help the prognosis of patients with acute liver failure. 8, 9 However, the efficacy of rescue antiviral therapy remains to be characterized in largescale clinical trials.
Furthermore, whether the cumulative rate of resistance to lamivudine in patients with chronic HBV infection following chemo therapy is comparable to that of immuno competent patients remains unclear. And, there is no clinical evidence indicating the superiority of lamivudine over other nucleo tide analogues as prophylactic antivirals.
Thus, agents with low incidences of resis tance, such as entecavir and tenofovir, might be better than lamivudine as firstline prophy lactic therapy. The work on prophy lactic antiviral therapy to prevent HBV reac tivation needs to be refined with the help of hepatologists. 
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